This is part of FJN’s Topic Briefs for Journalists series.
View COVERING PSYCHEDELICS main page
PHOTO Pexels/Merlin
In recent years, there has been a marked resurgence of mainstream interest in the use of psychedelics as tools for spiritual growth and the exploration of altered states of consciousness. This shift reflects a broader cultural movement toward experiential approaches to meaning-making, where subjective insight and emotional transformation are valued alongside conventional psychological frameworks.
Contemporary interest is closely linked to findings from scientific institutions where controlled studies have demonstrated that psychedelic experiences can occasion what participants describe as “mystical-type” or deeply meaningful states.
These experiences are often characterized by a sense of unity, transcendence of time and space, and a dissolution of the usual boundaries of the self. Importantly, such subjective effects have been correlated with long-term increases in well-being, life satisfaction, and openness to experience.
Beyond clinical settings, a growing number of individuals are seeking psychedelic experiences in structured, intentional environments, including retreats, guided sessions, and ceremonial contexts inspired by indigenous traditions.
At the same time, the mainstreaming of psychedelics raises important ethical and epistemological questions. The translation of substances rooted in indigenous and ceremonial use into Western therapeutic or self-development frameworks risks cultural appropriation and oversimplification. Moreover, while many report profound benefits, these experiences are highly context-dependent and can also be destabilizing without proper preparation and integration.
Overall, the renewed interest in psychedelics reflects a convergence of scientific validation, cultural openness, and a growing demand for transformative experiences. As research continues to evolve, psychedelics are increasingly positioned not only as clinical tools but as instruments for exploring consciousness and facilitating spiritual development in contemporary society.
From ancient rituals to modern rediscovery and cultural impact
In the history of science and culture only few topics bridge spirituality, medicine and controversy as deeply as psychedelia. Psychedelic substances have accompanied humankind for millennia—used by shamans, mystics, healers, and, more recently, scientists and artists.
Their story intertwines biology, psychology, religion, and rebellion. Today, as clinical research reawakens after decades of prohibition, we are once again rediscovering what ancient peoples already knew: that these compounds can profoundly alter consciousness and, when used responsibly, heal the human mind.
Long before modern chemistry, ancient societies used naturally occurring psychedelics as portals to the divine. These weren’t taken recreationally but reverently — bridges between the human and the sacred.
Psychedelics re-entered Western science at the turn of the 20th century. In 1897, Arthur Heffter isolated mescaline from peyote. Later, William James and Havelock Ellis experimented with it, documenting profound shifts in perception.
Then, in 1938, Albert Hofmann synthesized LSD while studying ergot alkaloids for pharmaceutical purposes. Five years later, he accidentally absorbed a small amount and experienced the world’s first acid trip—a mixture of wonder and confusion that changed psychiatry forever.
By the 1950s, psychedelics were hailed as revolutionary tools for psychology. Researchers like Stanislav Grof, Humphry Osmond, and Timothy Leary believed these substances could illuminate the unconscious mind. LSD therapy showed promise for alcoholism, depression, and trauma. More than 1,000 scientific papers and 40,000 subjects were studied in what many call the “first psychedelic renaissance.”
The suppression of psychedelic research in the late 1960s and 1970s was primarily driven by domestic political, regulatory, and cultural forces. The decisive regulatory shift occurred under U.S. President Richard Nixon. In 1970, the Controlled Substances Act (CSA) classified LSD, psilocybin, and other classic psychedelics as “Schedule I substances”, defined as:
- High potential for abuse
- No accepted medical use
- Lack of accepted safety under medical supervision
Before prohibition, psychedelics were studied at institutions like Harvard, UCLA, and Yale. However:
- Ethical standards were inconsistent.
- Some studies lacked modern informed consent protocols.
- Recreational leakage from research settings undermined credibility.
The emerging bioethics reforms of the 1970s (e.g., post-Tuskegee reforms) imposed stricter regulatory oversight, which psychedelic research was poorly positioned to meet at that moment.
The “psychedelic renaissance” began gradually, not suddenly. The regulatory breakthrough happened 1990–1994. In 1990, Rick Strassman received FDA approval to study DMT in humans — the first U.S. psychedelic study in decades. This demonstrated that Schedule I research was possible under strict compliance.
The institutional legitimization (2000s) took place at these key turning point institutions:
- The founding of the Multidisciplinary Association for Psychedelic Studies (MAPS), which strategically pursued FDA-compliant MDMA trials.
- The establishment of the Johns Hopkins Center for Psychedelic and Consciousness Research, which published rigorously controlled psilocybin studies beginning in the 2000s.
- Neuroimaging work at the Imperial College London Centre for Psychedelic Research, providing mechanistic brain data.
The publication of randomized controlled trials in major journals (e.g., JAMA Psychiatry, NEJM, Nature Medicine) between 2016–2023 marked definitive re-legitimization. MDMA-assisted therapy for PTSD entered Phase III trials under MAPS sponsorship — a level of regulatory progress unimaginable in the 1970s. Thus, the real inflection point was the demonstration that research on Schedule I substances could meet modern biomedical regulatory standards.
Today, psychedelics are once again moving from the fringes to the mainstream. In 2020, Oregon became the first U.S. state to legalize psilocybin therapy. Australia followed with MDMA- and psilocybin-assisted treatments for PTSD and depression. Major universities now run dedicated psychedelic research centers, and investors are pouring millions into biotech startups exploring novel compounds.
Psychedelics banned and criminalized
Psychedelic substances—including LSD, psilocybin (“magic mushrooms”), DMT, and related analogues—have long existed not only as countercultural symbols but also as black-market commodities within the global illicit drug trade. Although they represent a smaller share of overall revenues compared with cannabis, cocaine, and opioids, psychedelics are a significant component of transnational criminal networks that profit from prohibited psychoactive substances.
Although psychedelics are a smaller segment of the global illicit drug economy compared to cannabis, opioids, or cocaine, they remain an active and profitable component of black-market activity. Through darknet distribution, international trafficking networks, and syndicate involvement in production and sales, psychedelics contribute to the broader economic ecosystem of organized crime.
This dynamic underscores the broader consequences of prohibition: when markets are criminalized, production and distribution migrate into clandestine networks that generate substantial revenues for organized crime and complicate public health and law enforcement responses. See also Europol.
Written by Jesper Madsen for FJN
